Skip to main content
Alzheimer's Disease PsychosisDrugPhase 3

What this study is

This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP.

What's being tested

  • ACP-204

    Intervention · DRUG

    ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule

Study details

Official title
A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis
Sponsor
ACADIA Pharmaceuticals Inc.
Conditions
Alzheimer's Disease Psychosis
Enrolling
752 people
Starts
2024-04-23
Est. completion
2029-05
Design
Open-label, single group, Phase 3
Record
View on ClinicalTrials.gov ↗